

Management of Decongestion in Acute Heart Failure: Time for a New Approach?

Miftah Pramudyo¹, Iwan Cahyo Santosa Putra¹, Edrian Zulkarnain²,
Siska Suridanda Danny³, Hendry Purnasidha Bagaswoto⁴, Setyasih
Anjarwani⁵, Irmalita Mazwar³, Dafsah Arifa Juzar³, Vireza Pratama⁶, Faisal
Habib⁷, Akhtar Fajar Muzakkir Ali Aspar⁸, Bambang Widyantoro³

Abstract

As the primary cause of hospitalization in acute heart failure (AHF) patients, congestion was responsible for a higher risk of mortality, rehospitalization, and renal dysfunction in AHF patients. Although loop diuretic was routinely used as the mainstay of AHF therapy, it is still ineffective to obtain the euvolemic state in most hospitalized AHF patients. Therefore, a higher loop diuretic dose was often required to increase the decongestion effect. However, consequently, it can cause several detrimental complications, including renal dysfunction, neurohormonal activation, hyponatremia, hypokalaemia, and reduced blood pressure, which eventually result in poor prognosis. Hence, a new approach may be proposed to optimize decongestion in the acute phase, including the use of arginine vasopressin V2 receptor antagonist – Tolvaptan. As an additive therapy to loop diuretic in AHF patients, it can be considered due to its several beneficial effects, including greater decongestion effect, lowered worsening renal function incidence, counteract neurohormonal activation, neutralized hyponatremia state, no alteration of potassium metabolism, stabilize the blood pressure, and reduced requirement of a higher dose of loop diuretic to achieve an equal or even greater decongestion effect compared to a high dose of loop diuretic alone. Tolvaptan provided favorable outcomes in several specific populations and was considered safe with several mild adverse effects. Several guidelines across countries have approved the use of Tolvaptan in AHF patients with or without hyponatremia. The initial dose of Tolvaptan was 7.5 to 15 mg and can be titrated up to 30 mg. However, further studies were still required to determine the timing dose and optimal dose of Tolvaptan in general and elderly populations with AHF, respectively.

(Indonesian J Cardiol. 2022;43:77-89)

¹ Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia.

² Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia.

³ National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.

⁴ Dr. Sardjito General Hospital, Yogyakarta, Indonesia.

⁵ Dr. Saiful Anwar General Hospital, Malang, Indonesia.

⁶ Gatot Subroto Army Central Hospital, Jakarta, Indonesia.

⁷ Dr. Adam Malik General Hospital, Medan, Indonesia.

⁸ Dr. Wahidin Sudiro Husodo, Makassar, Indonesia.

Correspondence:

Miftah Pramudyo
Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia. Email: miftah.pramudyo@gmail.com

Keywords: Tolvaptan, a loop diuretic, congestion, acute heart failure.

Introduction

Hear failure (HF) becomes an increasing global concern as its prevalence reaches 64.34 million people worldwide, with numbers continuing to rise as populations expand and age.¹ A disabling and costly disease; HF is a global public health and economic burden.² When there is a rapid onset or acute worsening of symptoms and/or signs of heart failure, this is known as acute heart failure (AHF). AHF is a life-threatening disease that requires prompt treatment to improve mortality and morbidity outcomes.^{3,4}

Dyspnea, fatigue, and peripheral edema are the leading symptoms that occurred in patients admitted with AHF which delineate that congestion is the primary cause of hospitalization in AHF patients.⁵ A randomized clinical trial conducted by Damman et al. revealed that congestion was significantly associated with increased the risk of mortality, rehospitalization and renal dysfunction in AHF patients.⁶⁻⁸ A double-blind randomized controlled trial (RCT) conducted by Felker et al. found that 82 percent of AHF patients were still in a hypervolemic state after 72 hours despite the use of a high-dose loop diuretic.⁹ Consistently, based on post hoc analysis of two clinical trials, decongestion at discharge was only achieved in 52 percent of hospitalized AHF patients.⁸ It concludes that despite the use of loop diuretics as the mainstay strategy of decongestion therapy, it is still inadequate to achieve the euvolemic state in most hospitalized patients with AHF.

Although a higher dose of loop diuretic was significantly correlated with greater relief of dyspnea, net fluid loss, and body weight change, it was also associated with several detrimental outcomes including neurohormonal activation, worsening renal function (WRF), electrolyte abnormalities, arrhythmia, and hypotension resulting in increased mortality risk in AHF patients.⁹⁻²⁰ Consistently, several observational studies showed that higher dose of loop diuretics was independently associated with a higher risk of mortality, ICU admission, and longer hospitalization in AHF patients.²¹⁻²⁴ However, it is still controversial whether the direct deleterious effects of loop diuretic or greater severity disease were responsible to cause several disastrous outcomes in these studies.

Therefore, another alternative drug was essentially

needed as an add-on therapy to loop diuretic to escalate the success rate of decongestion and also prohibited other adverse effects related to loop diuretic. Thus, in this paper, we comprehensively review the new approach of decongestion therapy in AHF patients, with Tolvaptan as a candidate for adjunctive therapy on top of a loop diuretic.

Decongestion therapy in patients with acute heart failure

The European Society of Cardiology (ESC) 2021 guideline recommended loop diuretic as the first line therapy to reduce congestion in AHF due to its rapid onset of action and efficacy with class I recommendation.²⁵ Afterwards, if congestion is not relieved yet which is based on low urinary spot sodium after 2 hours (<50-70 mEq/L) and low urine output after 6 hours (<100-150 mL/h), a higher dose of loop diuretic and/or combination with another diuretic are considered with class I and IIa recommendation, respectively. Lastly, renal replacement therapy is utilized if all the pharmacological therapeutic efforts in achieving euvolemia in this population are failed, although it can impair kidney function.

Another therapeutic approach to facilitate decongestants in AHF has been reviewed previously, using dual nephron blockade with thiazide diuretics, natriuretic doses mineralocorticoid receptor antagonists. The addition of these two types of drugs aims to enhance the effect of loop diuretics.⁹ However, the strategy of combination diuretic therapy has not been prospectively evaluated in an adequately powered clinical trial. Meanwhile, other combination therapies with diuretics, such as nesiritide or low-dose (renal dose) dopamine, do not increase decongestants or improve renal function in patients with AHF.²⁶ According to the newest ESC guideline, only thiazide has been recommended as an additive diuretic therapy.²⁵ However, tolvaptan was mainly recommended in Asian guidelines including Japan, Thailand, China, and Korea.^{27-29,29}

Beneficial effects of Tolvaptan as add on therapy of loop diuretic in acute heart failure patients

In the human body, water balance was regulated by arginine vasopressin (AVP). A low circulatory volume which is indicated by arterial underfilling and

high osmolarity plasma was detected by baroreceptor (located in the left atrium, aortic arch, and carotid sinus) and osmoreceptor, respectively in the hypothalamus. Thereafter, supraoptic and paraventricular nuclei in the hypothalamus produce AVP.³⁰ Afterwards, this hormone will bind to vasopressin 2 (V2) receptors in the basolateral membrane in collecting tubules of the kidney and providing water reabsorption by activating the aquaporin 2 (AQP2) channel.³¹ Tolvaptan as a selective V2 receptor antagonist blocked this receptor and avoided water absorption through the APQ2 channel which eventually induced hypotonic diuresis.³² The efficacy of Tolvaptan as an add-on therapy compared to the high dose of loop diuretic in AHF patients was depicted in (Figure 1.)

A double-blind randomized clinical trial conducted by Felker et al. revealed that a higher dose of loop diuretic was significantly associated with greater relief of dyspnea, change in body weight, and net fluid loss.⁹ However, this study also stated that only 18 percent of AHF patients were euvolemic after 72 hours despite high-dose loop diuretic administration. Consistently, a post hoc analysis of Diuretic Optimization Strategy

Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trials also showed that half of discharged hospitalized AHF patients still develop congestion ranging from low to high-grade orthodema scores regardless of using adequate loop diuretic doses.⁸ It concludes that failure rates of congestion therapy using loop diuretics were still higher in AHF patients.

In 2020, a meta-analysis conducted by Luo et al. showed that Tolvaptan as an add-on therapy to loop diuretic was significantly associated with relieved dyspnea, increased urine output, and reduced edema and body weight compared to loop diuretic alone group in AHF patients.³³ Loop diuretic can reduce tissue congestion by promoting natriuresis and diuresis through inhibition of Na+K+Cl- co-transporter channel in the thick ascending limb of the loop of Henle.³⁴ While Tolvaptan can reduce tissue congestion by inducing hypotonic diuresis by suppressing the AQP2 channel in the collecting duct.³² Hypothetically, the synergistic diuresis effect by Tolvaptan and the loop of diuretic through inhibition of two disparate channels




Figure 1. Efficacy of Tolvaptan as adjunctive therapy to loop diuretic in management of acute heart failure.

in two renal sites was significantly associated with a greater decongestion effect. A randomized controlled trial (RCT) conducted by Matsue et al. found that Tolvaptan significantly induced a greater diuresis effect albeit a lower amount of loop diuretic use (80 mg vs 120 mg).³⁵ Consistently, RCT conducted by Kimura et al. revealed that additive Tolvaptan significantly increased urine output volume compared to the increased loop diuretic dosage group.³⁶ Thus, although in a lessened doses of loop diuretic, administration of Tolvaptan as an add-on therapy significantly reduced congestion in AHF patients compared to the loop diuretic group.

Tolvaptan and worsening renal function

WRF is defined as an increase in serum creatinine levels of more than 0.3 mg per decilitre or 50% above baseline within 48 hours after admission.^{9,15} WRF is one of the detrimental complications of AHF that occurred in 27-32% of AHF patients and significantly increased the risk of mortality in congested AHF patients.¹⁵⁻¹⁷ Additionally, aggressive use of loop diuretics in high-dose sets was correlated with worsening renal function in AHF patients.^{9,13,15,22} On the other hand, a meta-analysis conducted by Luo et al. revealed that tolvaptan, particularly in low doses (7.5-15 mg) as adjuvant therapy of loop diuretic was significantly associated with reduced incidence of WRF.³³ However, high dose Tolvaptan was associated with composite outcome. As mentioned earlier, serum sodium levels increased dose-dependently which pointed out that a high dose of Tolvaptan might profoundly increase serum sodium levels.³⁷ Furthermore, it can lead to the release of a greater amount of VAP to bind to the V1a receptor resulting in induced vasoconstriction and eventually promoting renal hypoperfusion.³⁸

Loop diuretics can alter the sodium concentration at the macula densa in the acute phase and decrease intravascular volume by its vasodilator, natriuresis, and diuresis effects in the chronic phase, resulting in reduced renal blood flow and eventually causing WRF.^{39,40} In contrast, Tolvaptan provided free-water diuresis and subsequently can increase the oncotic pressure in the intravascular resulting in preserved both intravascular volume and renal blood flow.⁴¹ Additionally, a randomized controlled trial conducted by Hanatani et al. investigated the urine volume and serum creatinine concentration in two comparing groups: low-dose

Tolvaptan (15 mg) with a fixed dose of loop diuretic group or half-dose of a loop diuretic. Tolvaptan with a half dose of loop diuretic was significantly associated with reduced mean serum creatinine concentration and no significant difference in urine volume between two groups. Consistently, two RCTs confirmed that additive Tolvaptan group in AHF patients significantly reduced WRF incidence yet increased urine output volume compared to the additive loop diuretic group.^{36,42} Thus, the incidence of WRF in AHF patients can be reduced by combination therapy of low-dose Tolvaptan and loop diuretic as a consequence of Tolvaptan's capability to counteract the adverse effects of loop diuretic and also limited the loop diuretic dose.

Tolvaptan and neurohormonal activation

Theoretically, the use of loop diuretics in acute settings can lead to macula densa stimulation, resulting in decreased renal blood flow and eventually causing renin-angiotensin-aldosterone system (RAAS) activation.⁴⁰ Subsequently, the angiotensin II will contribute to the sympathetic nervous system (SNS) and vasopressin activation, leading to vasoconstriction and deterioration of cardiac function in AHF patients.⁴³ Accordingly, two observational studies confirmed that loop diuretic significantly increased plasma renin activity (PRA) in HF patients.^{44,45} Moreover, an observational study conducted by Francis et al. showed that PRA, plasma norepinephrine level, and plasma arginine vasopressin level were significantly elevated in AHF patients within 10 minutes of loop diuretic administration.⁴⁰

On the contrary, the drug mechanism of Tolvaptan in maintaining the intravascular volume provides a beneficial effect in preventing neurohormonal activation in AHF patients. Additionally, Tolvaptan is also responsible to counteract the vasopressin activation through its capability to blockade the V2 receptor. Consistently, A RCT study conducted by Jujo et al. found that the furosemide group significantly enhanced PRA compared to the Tolvaptan group.⁴⁶ A previous meta-analysis that showed reduced WRF in additive low-dose Tolvaptan also indicated preservation of renal perfusion in this group which eventually avoided RAAS activation.³³ Thus, Tolvaptan as an add-on therapy to loop diuretic in AHF patients may nullify the neurohormonal activation and also avoid the overdose of loop diuretic which may prevent further

neurohormonal activation.

Tolvaptan and electrolytes

Electrolyte imbalance including hyponatremia and hypokalaemia often occurred in AHF settings which resulted in an increased risk of arrhythmic death.¹⁰ Hyponatremia in AHF patients was mainly caused by the release of AVP which lead to increased water reabsorption in the collecting duct, resulting in increased intravascular volume and diluting serum sodium concentrations.⁴⁷ In addition, loop diuretics can also cause hyponatremia through its natriuresis mechanism. Consistently, high-dose loop diuretic was significantly associated with hyponatremia incidence compared to low dose group in AHF patients.^{48,49} A study showed that a longer duration use of loop diuretic was positively correlated with hyponatremia.⁵⁰ Moreover, hyponatremia in admitted AHF patients was an independent predictor of longer hospitalization stays and mortality within 60 days from discharge.²⁰ Likewise, due to its free-water diuresis effect, Tolvaptan tends to increase serum sodium concentration.³² Consistently, Kim et al. study confirmed that Tolvaptan increased the serum sodium concentration with a dose-response related.³⁷ A meta-analysis by Luo et al. revealed that Tolvaptan as an add-on therapy of loop diuretic significantly increased serum sodium concentration in AHF patients.³³ Additionally, an RCT study conducted by Kimura et al. also showed that adjunctive Tolvaptan group was associated with increased serum sodium levels compared to increased loop diuretic dose group.⁴² This study reveals that three patients with hyponatremia were corrected to normonatremic states by Tolvaptan administration. Moreover, FDA previously also approved the application of Tolvaptan in hypervolemic hyponatremia in patients with HF.⁵¹ Thus, Tolvaptan can reduce the risk of hyponatremia in AHF patients through its direct mechanism of action and limited administration of loop diuretics in high-dose settings. Therefore, Tolvaptan can be recommended as adjunctive therapy in AHF patients, especially in patients with hyponatremic conditions.

On the other hand, hypokalaemia is another electrolytes abnormality that frequently occurred in AHF patients caused by the use of loop diuretics.¹¹ Its capability to inhibit potassium reabsorption in ascending limb of the loop of Henle was the primary cause of

hypokalaemia.⁵² Consistently, two observational studies showed that hypokalaemia was significantly associated with increased risk of mortality and risk of hospitalization in HF patients.^{18,19} However, Kim et al. study stated that Tolvaptan had no effects on potassium metabolism and did not alter the serum potassium concentration at any dose.³⁷ RCT conducted by Gheorghide et al. revealed that the adjunctive Tolvaptan group significantly increased potassium levels compared to the loop diuretic group.⁵³ Consistently, another RCT conducted by Tamaki et al. found that compared to the additive Tolvaptan group, the loop diuretic group significantly reduced potassium levels.⁵⁴ Hence, Tolvaptan might not increase the risk of hypokalaemia in AHF patients.

Tolvaptan and blood pressure

As described above, loop diuretics could deplete intravascular volume which resulted in lowered blood pressure.⁵⁵ Therefore, the incrementation of loop diuretic doses in AHF patients with borderline blood pressure remains challenging. In contrast, due to its potential to preserve intravascular volume, Tolvaptan did not affect blood pressure alteration. RCT conducted by Kimura et al. demonstrated that a higher dose of the loop diuretic group significantly reduced blood pressure in comparison to the additive Tolvaptan group.⁴² Consistently, several RCTs showed additive Tolvaptan group was associated with better maintenance of blood pressure whilst blood pressure in the loop diuretic group dropped significantly.^{35,46,56} Hence, it concludes that Tolvaptan as an additional therapy to loop diuretic appears to reverse the blood pressure-reducing effect of a loop diuretic.

Safety evaluation of Tolvaptan

Mortality, rehospitalization, and Hospitalization Duration in AHF Patients

A meta-analysis involving of 7 RCTs revealed that Tolvaptan as adjunctive therapy did not significantly increased the mortality risk yet not reduced the in-hospital mortality risk compared to conventional use of loop diuretic in AHF patients. Furthermore, four RCTs found that rehospitalization rate was not different between additive Tolvaptan group and loop diuretic group.^{35,56-58} Moreover, 3 RCTs confirmed that

Tolvaptan group was not increased yet reduced length of hospital stay as opposed to loop diuretic group.^{35,46,58} Thus, the use of Tolvaptan as addition therapy was appreciably safe in AHF patients.

Tolvaptan in specific populations

Tolvaptan in chronic kidney disease patients

Until now, AHF treatment in the chronic kidney disease population remains challenging. In CKD patients, a higher dose of loop diuretic above the threshold level (80-160 mg) was required to obtain the equal decongestion effect as in normal kidney function patients.⁵⁹ However, it is widely known that increasing the dose of loop diuretic had several detrimental outcomes as described above.

A meta-analysis conducted by Sen et al. investigated the diuresis effect and renal function in the additive Tolvaptan group compared to the loop diuretic group in HF patients with CKD.⁶⁰ This meta-analysis showed that creatinine concentration and glomerular filtration rate (GFR) were not significantly different between the two groups. Moreover, surprisingly, the diuresis effect indicated by urine flow rate was significantly increased in the additive Tolvaptan group compared to the loop diuretic group. An observational study conducted by Otsuka et al. found that additive Tolvaptan use in CHF patients with stage 5 CKD significantly reduced serum creatinine concentration compared to baseline.⁶¹ Additionally, an RCT study from Japan investigated the 24-hour urine output volume and several safety parameters in hemodialysis patients with the adjunctive Tolvaptan group compared to the loop diuretic group.⁶² Adjunctive Tolvaptan group significantly increased 24-hours urine output volume in week 2 compared to the loop diuretic group and consistently higher until the end of the study. However, 24-hours urine output volume in the loop diuretic group appears to decrease up to week 2 and remains constant until the end of the study. Moreover, there were no significant adverse effects, no obvious changes in laboratory findings (serum sodium, creatinine, blood urea nitrogen, etc), and no significant findings on electrocardiographic (ECG) and vital signs in the adjunctive Tolvaptan group.

Furthermore, an RCT study conducted by Inomata et al analyzed the renal function and diuresis effect in the

additive Tolvaptan group (≤ 15 mg/day) compared to the additive furosemide group (≤ 40 mg/day) in AHF with renal dysfunction ($GFR < 45$ ml/min/1.73m²) which previously has been treated with furosemide in certain doses (≥ 40 mg/day). This RCT study revealed that the additive Tolvaptan group significantly reduced WRF incidence and serum creatinine levels, and increased urine output volume compared to the additive furosemide group.³⁶ Thus, it appears that additive Tolvaptan use in AHF patients with CKD was considered safe and had a greater decongestion effect albeit in a lower dose of loop diuretic.

Tolvaptan in the elderly population

Several RCTs comprising mainly of the elderly population showed that compared to the loop diuretic group, Tolvaptan as adjunctive AHF treatment was significantly associated with relieved dyspnea, reduced edema, increased serum sodium levels, and reduced WRF incidence, particularly in low-dose Tolvaptan (7.5-15 mg).^{9,35,36,42,46,53,54,57}

There are one clinical trial and one observational study which investigated the comparison of efficacy and safety of Tolvaptan use in the elderly population and young population. A clinical trial conducted by Niikura et al. found that there were no significant differences in urine output volume, WRF incidence, serum creatinine levels, blood pressure, hypotension incidence, hyponatremia, and hypokalaemia incidence, length of hospital stay, and all-cause death between elderly and young participants.⁶³ Consistently, a retrospective study by Matsukawa et al also revealed that the beneficial effects of Tolvaptan in the elderly group were not significantly different in the young group.⁶⁴

However, based on an observational study conducted by Kinigawa et al., the elderly population tends to experience hypernatremia compared to the young participant, especially if concurrently using a high dose of Tolvaptan (15 mg).⁶⁵ Thus, although the administration of Tolvaptan was appreciably safe and effective in the elderly population, careful observation of serum sodium levels was needed to prevent hypernatremia incidence in this population.

Tolvaptan in hypoalbuminemia patients

Hypoalbuminemia was responsible for the increased

risk of mortality in AHF patients.⁶⁶ Hypoalbuminemia lowered the intravascular oncotic pressure while concurrently disrupting the delivery of drugs which lead to volume overload and diuretic resistance in AHF patients, respectively.⁶⁷ Nonetheless, a retrospective study by Takagi et al showed that administration of Tolvaptan significantly increased urine output in hospitalized HF patients with hypoalbuminemia.⁶⁸ Hence, Tolvaptan can be administered as an additive therapy in AHF patients who have hypoalbuminemia to improve the diuresis effect.

Adverse effects of Tolvaptan

Despite of many beneficial effects of Tolvaptan as adjunctive therapy of AHF, two RCTs confirmed that compared to the conventional use of the loop diuretic group, additive Tolvaptan significantly increased the risk of several adverse effects including dry mouth, thirst, and polyuria.^{53,69} Moreover, Konstam et al. study found that hypernatremia incidence was not significantly different between the additive Tolvaptan group and loop diuretic group in AHF patients.⁵⁷ RCT study conducted by Matsue et al. reported that there are no serious complications in five hypernatremia patients in Tolvaptan group and all of these patients retrieved spontaneously without any hypernatremia correction therapy after ceasing Tolvaptan administration.³⁵ Thus, currently, Tolvaptan utilization in AHF were considerably safe with only mild and tolerable adverse effects.

Current guideline recommendation, timing dose, and initial dose of Tolvaptan

Current guideline recommendations

Several guidelines that were initiated in 8 different countries approved the use of Tolvaptan in AHF.^{25,27-29,70-72} Guidelines from America, Canada, Europe, and Korea only recommended Tolvaptan administration in particularly AHF patients with persistent hyponatremia and congestion.^{25,29,70,71} Nevertheless, guidelines from Japan, China, and Thailand recommended the use of Tolvaptan in AHF patients who are not responding well to loop diuretics or hyponatremia.^{27,28,72} Therefore, based on these three guidelines, Tolvaptan can be used as additive therapy in AHF patients who have persistent

congestion despite being off without hyponatremia. However, its administration was contraindicated in hypernatremia patients.^{27,73} Several Guideline recommendations of Tolvaptan administration in AHF were elaborated in (Table 1.)

Timing dose of Tolvaptan

A retrospective cohort study conducted by Mastsukawa et al. found that compared to the late group (>3 days), early use of Tolvaptan within 3 days after admission in ADHF patients was associated with Tolvaptan responsiveness (24-hours total urine output >150% than baseline), reduced hospitalization duration, in-hospital mortality, rehospitalization due to worsening heart failure and all-cause death within 1 year after discharge.⁶⁴ Moreover, Matsukawa et al. performed another retrospective cohort study comparing the early group versus the late group of Tolvaptan administration in the elderly population with ADHF. Similar results were obtained in which the early group was associated with Tolvaptan responsiveness and decreased length of hospitalization and in-hospital mortality.⁷⁴ Furthermore, another retrospective cohort study conducted by Kiuchi et al. showed that early utilization of Tolvaptan within 4 days of admission was significantly associated with reduced length of hospital stay.⁷⁵ Although without a control group of late use of Tolvaptan, these two RCTs confirmed that administration of Tolvaptan as adjunctive therapy in ADHF patients within 24 hours was associated with reduced risk of WRF incidence and increased body weight and fluid loss compared to loop diuretic group.^{9,42} Therefore, the early use of Tolvaptan was preferred compared to late use because of its several favorable outcomes in AHF patients. Based on the satisfactory result of early use of Tolvaptan in the Matsukawa et al. study, Imamura and Kinugawa give their expert opinion that Tolvaptan may be considered in the second 60 minutes when refractory congestion occurred despite of administration of loop diuretic in the first hour of AHF patients' admission.⁷⁶ However, no guideline has stated the timing dose of Tolvaptan; hence, several RCTs are still required to determine the appropriate timing dose of Tolvaptan.

The initial dose of Tolvaptan

A dose of 7.5 mg to 15 mg was recommended as an initial dose of Tolvaptan in general AHF patients by the

Table 1. Guideline recommendations of Tolvaptan as additive therapy in acute heart failure.

Country	Year	Guidelines	Recommendation	Level of evidence
US	2013	ACCF/AHA Guideline for the Management of Heart Failure ⁷⁰	In patients hospitalized with volume overload, including HF, who have persistent severe hyponatremia and are at risk for or having active cognitive symptoms despite water restriction and maximization of GDMT, vasopressin antagonists may be considered in the short term to improve serum sodium concentration in hypervolemic, hyponatremic states with either a V2 receptor selective or a nonselective vasopressin antagonist.	Class IIb, level of evidence B
Canada	2012	The Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure ⁷¹	We recommend tolvaptan be considered for patients with symptomatic or severe hyponatremia (130 mmol/L) and persistent congestion despite standard therapy, to correct hyponatremia and the related symptoms	Weak Recommendation, Moderate-Quality Evidence
Europe	2021	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure ²⁵	Tolvaptan, an orally active selective arginine vasopressin V2 receptor antagonist, can be considered to increase serum sodium and diuresis in patients with persistent hyponatraemia and congestion	-
Japan	2017	JCS/JHFS Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure ²⁷	Use for the treatment of fluid retention in patients not responding well to other diuretics including loop diuretics (Excluding patients with hypernatremia) Use for the treatment of fluid retention in patients with hyponatremia	Class IIa, level of evidence A Class IIa, level of evidence C
Thailand	2019	Heart Failure Council of Thailand (HFCT) Heart Failure Guideline: Acute Heart Failure ²⁸	Heart Failure Council of Thailand (HFCT) Heart Failure Guideline: Acute Heart Failure ²⁸	Class IIa, level of evidence B
China	2018	Chinese guidelines for the diagnosis and treatment of heart failure ⁷²	Tolvaptan is recommended to use for patients with congestive HF, poor response to conventional diuretics, hyponatremia or tendency to renal impairment, it could significantly improve congestion related symptoms without obvious short-term and long-term adverse drug reactions	Class IIb, level of evidence B
Korea	2017	Korea Guidelines for Diagnosis and Management of Chronic Heart Failure ²⁹	Use of a vasopressin antagonist may be considered in patients with HF and refractory hyponatremia	Class IIb, level of evidence B

ACCF: American Council for Capital Formation; AHA: American Heart Association; ESC: European Society of Cardiology; JCS: Japan Circulation Society; JHFS: Japanese Heart Failure Society; HF: heart failure; GDMT: guideline-directed medical therapy.

Chinese Society of Cardiology (CSC) guideline in 2018 and the JCS guideline in 2017.^{27,72} However, until now, no studies are comparing certain doses of Tolvaptan in AHF patients. Thus, the recommendation of this particular dose was only based on its potential effect to significantly reduced WRF incidence in AHF patients compared to the high-dose Tolvaptan group (30 mg).³³ Moreover, Tolvaptan dose could be titrated up to 30 mg based on its efficacy.⁷²

However, the adjusted dose was necessitated especially in the elderly population because this population was more likely to acquire hypernatremia, particularly after the use of a 15 mg dose of Tolvaptan.⁶⁵ Therefore, due to the high risk of hypernatremia and WRF incidence, a low dose (3.75 mg) of Tolvaptan was recommended as the initial dose in the elderly population.⁷⁶

Conclusion

In conclusion, although decongestion therapy in AHF is still challenging, Tolvaptan can be used as additive therapy to conventional loop diuretics in the management of AHF due to its several beneficial effects including promoting greater decongestion effect, reduced incidence of WRF, nullified neurohormonal activation, neutralized hyponatremic state, no alteration of serum potassium levels, maintained the blood pressure and reduced the use of higher loop diuretic dose to obtain an equal or even greater decongestion effect compared to high dose loop diuretic alone. Additionally, Tolvaptan still provided favorable outcomes in several specific populations such as the elderly, CKD, and hypoalbuminemia. Furthermore, Tolvaptan was considerably safe due to its capability to not increased mortality risk, rehospitalization, and prolonged hospitalization duration. Tolvaptan had tolerable and mild adverse effects such as thirst, dry mouth, polyuria, and mild hypernatremia. Moreover, several guidelines across countries also approved the use of Tolvaptan in the AHF setting. Lastly, further RCTs were still needed to determine the timing dose of Tolvaptan in the general population with AHF and the initial dose of Tolvaptan in elderly patients with AHF.

References

1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1789–858.
2. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol*. 2014 Apr 1;63(12):1123–33.
3. Lan T, Liao YH, Zhang J, Yang ZP, Xu GS, Zhu L, et al. <p>Mortality and Readmission Rates After Heart Failure: A Systematic Review and Meta-Analysis</p>. *TCRM*. 2021 Dec 7;17:1307–20.
4. Kurmani S, Squire I. Acute Heart Failure: Definition, Classification and Epidemiology. *Curr Heart Fail Rep*. 2017;14(5):385–92.
5. Ural D, Çavuşoğlu Y, Eren M, Karüzüm K, Temizhan A, Yılmaz MB, et al. Diagnosis and management of acute heart failure. *Anatol J Cardiol*. 2016 Nov;15(11):860–89.
6. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. *Eur J Heart Fail*. 2010 Sep;12(9):974–82.
7. Waranugraha Y, Rohman MS, Anjarwani S. Hemodynamic Congestion at Hospital Discharge Predicts Rehospitalization during Short Term Follow Up in Acute Heart Failure Patients. *Indonesian Journal of Cardiology* [Internet]. 2019 Sep 11 [cited 2022 Jan 16];40(3). Available from: <https://www.ijconline.id/index.php/ijc/article/view/805>
8. Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. *Circulation: Heart Failure* [Internet]. 2015 Jul [cited 2022 Jan 15]; Available from: <https://www.ahajournals.org/doi/abs/10.1161/CIRCHEARTFAILURE.114.001957>
9. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic Strategies in Patients with Acute Decompensated

- Heart Failure. *New England Journal of Medicine*. 2011 Mar 3;364(9):797–805.
10. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. *Circulation*. 1999 Sep 21;100(12):1311–5.
 11. Arampatzis S, Funk GC, Leichtle AB, Fiedler GM, Schwarz C, Zimmermann H, et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis. *BMC Medicine*. 2013 Mar 27;11(1):83.
 12. Damman K, Valente MAE, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J*. 2014 Feb;35(7):455–69.
 13. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. *Am Heart J*. 2004 Feb;147(2):331–8.
 14. Palazzuoli A, Ruocco G, Ronco C, McCullough PA. Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. *Critical Care*. 2015 Dec 1;19(1):296.
 15. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. *Eur J Heart Fail*. 2008 Feb;10(2):188–95.
 16. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. *J Am Coll Cardiol*. 2004 Jan 7;43(1):61–7.
 17. Yamada T, Ueyama H, Chopra N, Yamaji T, Azushima K, Kobayashi R, et al. Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. *Kidney Int Rep*. 2020 Jul 2;5(9):1486–94.
 18. Aldahl M, Jensen ASC, Davidsen L, Eriksen MA, Møller Hansen S, Nielsen BJ, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. *European Heart Journal*. 2017 Oct 7;38(38):2890–6.
 19. Savarese G, Xu H, Trevisan M, Dahlström U, Rossignol P, Pitt B, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. *JACC Heart Fail*. 2019 Jan;7(1):65–76.
 20. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. *Circulation*. 2005 May 17;111(19):2454–60.
 21. Philbin EF, Cotto M, Rocco TA, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. *Am J Cardiol*. 1997 Aug 15;80(4):519–22.
 22. Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. *Cardiology*. 2009;113(1):12–9.
 23. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. *Eur J Heart Fail*. 2007 Oct;9(10):1064–9.
 24. Miura M, Sugimura K, Sakata Y, Miyata S, Tadaki S, Yamauchi T, et al. Prognostic Impact of Loop Diuretics in Patients With Chronic Heart Failure – Effects of Addition of Renin-Angiotensin-Aldosterone System Inhibitors and β -Blockers –. *Circulation Journal*. 2016;80(6):1396–403.
 25. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*. 2021 Sep 21;42(36):3599–726.

26. Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, et al. Tolvaptan in Patients Hospitalized With Acute Heart Failure. *Circulation: Heart Failure*. 2015 Sep;8(5):997–1005.
27. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure- Digest Version. *Circ J*. 2019 Sep 25;83(10):2084–184.
28. Phrommintikul A, Buakhamsri A, Janwanishstaporn S. Heart Failure Council of Thailand (HFCT) 2019 Heart Failure Guideline: Acute Heart Failure. *J Med Assoc Thai*. 2019;102:373-9.
29. Kim MS, Lee JH, Kim EJ, Park DG, Park SJ, Park JJ, et al. Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. *Korean Circ J*. 2017 Sep;47(5):555–643.
30. Lee CR, Watkins ML, Patterson JH, Gattis W, O’connor CM, Gheorghiadu M, et al. Vasopressin: a new target for the treatment of heart failure. *Am Heart J*. 2003 Jul;146(1):9–18.
31. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frøkiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. *J Am Soc Nephrol*. 1999 Mar;10(3):647–63.
32. Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. *J Pharmacol Sci*. 2014;124(1):1–6.
33. Luo X, Jin Q, Wu Y. Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis. *Pharmacol Res Perspect*. 2020 Jun;8(3):e00614.
34. Feig PU. Cellular mechanism of action of loop diuretics: implications for drug effectiveness and adverse effects. *Am J Cardiol*. 1986 Jan 24;57(2):14A-19A.
35. Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, et al. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. *J Card Fail*. 2016 Jun;22(6):423–32.
36. Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment-Results From the K-STAR Study. *Circ J*. 2017 Dec 25;82(1):159–67.
37. Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. *Cardiovasc Drugs Ther*. 2011 Dec;25 Suppl 1:S5-17.
38. Birnbaumer M. Vasopressin receptors. *Trends Endocrinol Metab*. 2000 Dec;11(10):406–10.
39. Patschan D, Patschan S, Buschmann I, Ritter O. Loop Diuretics in Acute Kidney Injury Prevention, Therapy, and Risk Stratification. *KBR*. 2019;44(4):457–64.
40. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. *Ann Intern Med*. 1985 Jul;103(1):1–6.
41. Sr G, Ba B, J B. Decongestive therapy and renal function in acute heart failure: time for a new approach? *Circulation Heart failure* [Internet]. 2014 May [cited 2022 Jan 20];7(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/24847128/>
42. Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. *J Cardiol*. 2016 May;67(5):399–405.
43. Hartupej J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. *Nat Rev Cardiol*. 2017 Jan;14(1):30–8.
44. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation*. 1990 Nov;82(5):1724–9.
45. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. *Br Heart J*. 1987 Jan;57(1):17–22.
46. Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. *ESC Heart Fail*. 2016 Sep;3(3):177–88.

47. Oren RM. Hyponatremia in congestive heart failure. *Am J Cardiol.* 2005 May 2;95(9A):2B-7B.
48. Yamazoe M, Mizuno A, Kohsaka S, Shiraiishi Y, Kohno T, Goda A, et al. Incidence of hospital-acquired hyponatremia by the dose and type of diuretics among patients with acute heart failure and its association with long-term outcomes. *Journal of Cardiology.* 2018 Jun 1;71(6):550–6.
49. Velat I, Bušić Ž, Jurić Paić M, Čulić V. Furosemide and spironolactone doses and hyponatremia in patients with heart failure. *BMC Pharmacol Toxicol.* 2020 Aug 3;21:57.
50. Guan Y, Wu X, Xu M, Wu J. [Impact of loop diuretics on blood sodium in patients hospitalized for heart failure]. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2014 Jul;42(7):582–7.
51. Research C for DE and. FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. *FDA* [Internet]. 2019 Jun 21 [cited 2022 Jan 18]; Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-duration-and-usage-samsca-tolvaptan-due-possible-liver>
52. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. *Expert Opin Pharmacother.* 2014 Apr;15(5):605–21.
53. Gheorghide M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA.* 2007 Mar 28;297(12):1332–43.
54. Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, et al. Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction- Prospective Randomized Controlled Study. *Circ J.* 2017 Apr 25;81(5):740–7.
55. Davidov M, Kakaviatos N, Finnerty FA. Antihypertensive properties of furosemide. *Circulation.* 1967 Jul;36(1):125–35.
56. Shanmugam E, Doss CRMP, George M, Jena A, Rajaram M, Ramaraj B, et al. Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial. *Indian Heart Journal.* 2016 Apr 1;68:S15–21.
57. Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, et al. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. *J Am Coll Cardiol.* 2017 Mar 21;69(11):1409–19.
58. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, et al. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. *J Am Coll Cardiol.* 2017 Mar 21;69(11):1399–406.
59. Wilcox CS. New insights into diuretic use in patients with chronic renal disease. *J Am Soc Nephrol.* 2002 Mar;13(3):798–805.
60. Sen J, Chung E, McGill D. Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. *Heart Lung Circ.* 2018 Aug;27(8):928–39.
61. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. *Clin Exp Nephrol.* 2013 Dec;17(6):834–8.
62. Ogata H, Shimofurutani N, Okada T, Nagamoto H, Akizawa T. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial. *Nephrology Dialysis Transplantation.* 2021 Jun 1;36(6):1088–97.
63. Niikura H, Iijima R, Anzai H, Kogame N, Fukui R, Takenaka H, et al. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure. *Anatol J Cardiol.* 2017 Sep;18(3):206–12.
64. Matsukawa R, Kubota T, Okabe M, Yamamoto Y. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. *Heart Vessels.* 2016 Oct;31(10):1650–8.
65. Kinugawa K, Sato N, Inomata T, Yasuda M, Shibasaki Y, Shimakawa T. Novel Risk Score Efficiently Prevents Tolvaptan-Induced Hypernatremic Events in Patients With Heart Failure. *Circ J.* 2018 Apr 25;82(5):1344–50.
66. Uthamalingam S, Kandala J, Daley M, Patvardhan E, Capodilupo R, Moore SA, et al. Serum albumin

- and mortality in acutely decompensated heart failure. *Am Heart J*. 2010 Dec;160(6):1149–55.
67. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. *Kidney Int*. 1987 Aug;32(2):198–203.
 68. Takagi K, Sato N, Ishihara S, Sone M, Tokuyama H, Nakama K, et al. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. *Heart Vessels*. 2018 Apr;33(4):413–20.
 69. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O'Brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. *J Card Fail*. 2011 Dec;17(12):973–81.
 70. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Circulation*. 2013 Oct 15;128(16):e240–327.
 71. McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. *Can J Cardiol*. 2013 Feb;29(2):168–81.
 72. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2018]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2018 Oct 24;46(10):760–89.
 73. Bambang B. Siswanto, Nani Hersunarti. Konsensus Tatalaksana Cairan Pada Gagal Jantung. *Perhimpunan Dokter Spesialis Kardiovaskular Indonesia*. 2020;
 74. Matsukawa R, Kubota T, Okabe M, Yamamoto Y, Meno H. Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure. *Heart Vessels*. 2018 Feb;33(2):145–54.
 75. Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, et al. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. *Heart Vessels*. 2018 Apr 1;33(4):367–73.
 76. Imamura T, Kinugawa K. Update of acute and long-term tolvaptan therapy. *J Cardiol*. 2019 Feb;73(2):102–7.